- Home
- BTBD vs CLDI Comparison
BTBD vs CLDI Comparison
Compare BTBD & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBD
- CLDI
- Stock Information
- Founded
- BTBD 1987
- CLDI 2014
- Country
- BTBD United States
- CLDI United States
- Employees
- BTBD N/A
- CLDI N/A
- Industry
- BTBD Restaurants
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BTBD Consumer Discretionary
- CLDI Health Care
- Exchange
- BTBD Nasdaq
- CLDI Nasdaq
- Market Cap
- BTBD 8.7M
- CLDI 9.9M
- IPO Year
- BTBD 2021
- CLDI N/A
- Fundamental
- Price
- BTBD $1.40
- CLDI $1.33
- Analyst Decision
- BTBD
- CLDI
- Analyst Count
- BTBD 0
- CLDI 0
- Target Price
- BTBD N/A
- CLDI N/A
- AVG Volume (30 Days)
- BTBD 164.3K
- CLDI 235.2K
- Earning Date
- BTBD 11-17-2025
- CLDI 11-13-2025
- Dividend Yield
- BTBD N/A
- CLDI N/A
- EPS Growth
- BTBD N/A
- CLDI N/A
- EPS
- BTBD N/A
- CLDI N/A
- Revenue
- BTBD $14,038,307.00
- CLDI N/A
- Revenue This Year
- BTBD N/A
- CLDI N/A
- Revenue Next Year
- BTBD N/A
- CLDI N/A
- P/E Ratio
- BTBD N/A
- CLDI N/A
- Revenue Growth
- BTBD N/A
- CLDI N/A
- 52 Week Low
- BTBD $1.00
- CLDI $1.10
- 52 Week High
- BTBD $5.60
- CLDI $27.63
- Technical
- Relative Strength Index (RSI)
- BTBD 44.37
- CLDI 37.96
- Support Level
- BTBD $1.22
- CLDI $1.29
- Resistance Level
- BTBD $1.61
- CLDI $1.56
- Average True Range (ATR)
- BTBD 0.15
- CLDI 0.14
- MACD
- BTBD -0.02
- CLDI -0.01
- Stochastic Oscillator
- BTBD 51.79
- CLDI 40.68
About BTBD BT Brands Inc.
BT Brands Inc operates and owns a fast-food restaurant called Burger Time. The company also operates in Minnesota as a franchisee of Dairy Queen. It offers a variety of burgers and other affordably priced foods such as chicken sandwiches, pulled pork sandwiches, chicken chunks, side dishes, and soft drinks.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.